Previous close | 14.17 |
Open | 14.33 |
Bid | 13.95 x 150000 |
Ask | 14.23 x 150000 |
Day's range | 14.33 - 14.33 |
52-week range | 6.24 - 32.71 |
Volume | |
Avg. volume | 825 |
Market cap | 2.248B |
Beta (5Y monthly) | 2.33 |
PE ratio (TTM) | 179.12 |
EPS (TTM) | 0.08 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 59.88 |
It is hard to get excited after looking at TG Therapeutics' (NASDAQ:TGTX) recent performance, when its stock has...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at htt